Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid plus vitamin D leads to higher number of participants achieving 'response' by PGA compared with steroid (high certainty).
1 finding from 1 review
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'clearance' by IGA compared with steroid (moderate certainty).
1 finding from 1 review
Number of participants achieving 'response' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by IGA compared with steroid (moderate certainty).
1 finding from 1 review
Quality of life · scalp psoriasis
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid plus vitamin D showed no clear difference in number of participants withdrawing due to adverse events (AE) compared with steroid (moderate certainty).
1 finding from 1 review
PTH · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Number without 30% fall in PTH on two occasions · patients with bone disease in children with chronic kidney disease
Vitamin D preparations may leads to lower number without 30% fall in PTH on two occasions compared with placebo/no treatment (low certainty).
1 finding from 1 review
Hypercalcaemia · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Change in calcium‐phosphorus product mg(2)/dL(2) · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in all‐cause mortality (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in symptomatic catheter‐related thrombosis (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no VKA (very low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in major bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in minor bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review